Trial Profile
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of ZGN-440 (Subcutaneous Beloranib in Suspension) in Obese Subjects With Type 2 Diabetes Mellitus to Evaluate Weight Reduction, Glycemic Control, Safety, and Tolerability
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Beloranib (Primary)
- Indications Obesity
- Focus Adverse reactions; Therapeutic Use
- Sponsors Zafgen
- 11 Jul 2018 Results evaluating efficacy and safety of Beloranib were published in the Diabetologia.
- 11 Jun 2016 The FDA placed a full clinical hold on the beloranib IND in December 2015, according to a Zafgen media release.
- 11 Jun 2016 According to a Zafgen media release, results from this trial were presented at the American Diabetes Association's 76th Scientific Sessions.